FDMT4D Molecular Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of 4D Molecular Therapeutics, Inc. against SIC 2836 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDMT본 종목 | — | — | — | — | 230194.6%#1 | 12.9%#2 | -187.2%#2 | -34.4%#1 | -44.7%#1 | — | 4.8%#1 | — |
| MGTX | $911M#1 | 10.9x#1 | — | 11.2x#1 | 144.6%#2 | 22.7%#1 | -130.2%#1 | — | — | — | — | — |
| SANA | $766M#2 | — | 5.0x#1 | — | — | 8.5%#3 | — | -158.0%#2 | — | — | -47.6%#2 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-11-01.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice